{
    "nct_id": "NCT05243797",
    "official_title": "Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation - MajesTEC-4",
    "inclusion_criteria": "* Must have a new diagnosis of multiple myeloma according to IMWG criteria and have received induction +/- consolidation.\n* Must have received only one line of therapy and achieved at least a partial response (≥PR) as per IMWG 2016 response criteria (Kumar 2016) without evidence of progression at the time of first treatment dose.\n* Must not be intolerant to the starting dose of lenalidomide.\n* Must not have received any maintenance therapy.\n* Have an ECOG performance status score of 0, 1, or 2 at screening and immediately prior to the start of administration of study treatment\n* Have clinical laboratory values within prespecified range.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Received any prior BCMA-directed therapy.\n* Any previous therapy with an immune cell redirecting agent or gene modified adoptive cell therapy (eg, chimeric antigen receptor modified T cells, NK cells).\n* Discontinued treatment due to any AE related to lenalidomide as determined by the investigator.\n* Progressed on multiple myeloma therapy at any time prior to screening.\n* Received a cumulative dose of corticosteroids equivalent to ≥140 mg of prednisone within the 14 days prior to first treatment dose.\n* Received a live, attenuated vaccine within 4 weeks before first treatment dose. Non-live vaccines or non-replicating authorized for emergency use (eg. COVID-19) are allowed.",
    "miscellaneous_criteria": ""
}